XWEL vs CDNA

Head-to-Head Stock Analysis & Investment Rating

Last Updated: Nov 11, 2026

XWEL

38.8
AI Score
VS
XWEL Wins

CDNA

24.9
AI Score

Investment Advisor Scores

XWEL

39score
Recommendation
SELL

CDNA

25score
Recommendation
SELL

AI Analyst Insights

AI insights temporarily unavailable

Detailed Metrics Comparison

Metric XWEL CDNA Winner
Revenue 13.78M 389.01M CDNA
Net Income -13.44M 132.74M CDNA
Net Margin -97.5% 34.1% CDNA
Operating Income -7.52M 122.53M CDNA
ROE 725.0% 28.4% XWEL
ROA -65.5% 20.7% CDNA
Total Assets 20.53M 641.46M CDNA
Cash 11.78M 250.48M CDNA
Current Ratio 2.27 2.31 CDNA
Free Cash Flow -9.68M 40.36M CDNA

Relative Price Performance (Last 90 Days)

XWEL 1M: -29.3% · 3M: -43.2% CDNA 1M: +16.8% · 3M: +67.9%

Current Technical Phase

XWEL

Markdown
Sell / avoid

Price below a falling SMA50 (slope -14.5%), weak momentum, RSI 30

RSI (14): 30.1 · Price: $0.53

CDNA

Markup
Hold / add on dips

Price above SMA50, rising 50-day trend (20.7% over 20 days), RSI 55

RSI (14): 54.7 · Price: $77.88

Fundamentals Snapshot

Metric XWEL CDNA
Market Cap — —
Forward P/E 10.8 49.8
Trailing P/E — 33.0
Revenue (TTM) — —
Revenue Growth -0.1% 0.4%
Gross Margin 0.3% 0.7%
Operating Margin -0.4% 0.0%
EPS -5.24 2.37
Dividend Yield — —

Frequently Asked Questions

Based on our detailed analysis, XWEL is currently the stronger investment candidate, winning 1 of the key financial metrics based on our comprehensive scoring model.

We analyze revenue and earnings growth rates in the "Growth" section above. Generally, the company with higher year-over-year revenue and EPS growth is fostering better expansion. Check the table above for the specific growth percentages.

Valuation is determined by metrics like the P/E Ratio and PEG Ratio. A lower P/E typically suggests a stock is cheaper relative to its earnings. Refer to the "Valuation" section in our comparison table to see which stock currently trades at a more attractive multiple.